ABCL Stock Recent News

AbCellera is shifting its focus from a platform biotech company to its internal drug pipeline. The company's lead asset, ABCL575, comes with a variety of risks, but in our opinion, has a value of a little over $1B and is derisked based on comparable therapeutics. AbCellera is on track to submit ABCL575 for clinical trials in Q22025, helping the market reset its valuation on the company closer to the value of the lead asset.

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024.

AbCellera's Q2 2024 revenue declined by 27% year-over-year to $7.3 million. The company's net loss widened to $36.9 million due to increased R&D expenses. AbCellera's cash and marketable securities totaled $697.6 million, with total liquidity exceeding $900 million.

AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.11 per share a year ago.

Penny stocks represent an interesting investment opportunity.

The Baker brothers acquired millions of shares of AbCellera Biologics and Fate Therapeutics during the first months of 2024. AbCellera Biologics is a drug discovery business with a hand in more than a dozen experimental drugs in clinical-stage development.

AbCellera Biologics (ABCL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024.

AbCellera Biologics is a biotechnology company built to discover new antibodies for other drugmakers. The stock has fallen more than 90% from its all-time high and by 57% from a peak it set last summer.

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024.